[2020: Evidence-Based Medicine odyssey. The fall and rise of evidence-based medicine in the year of coronavirus]

Recenti Prog Med. 2021 Jan;112(1):15-18. doi: 10.1701/3525.35118.
[Article in Italian]

Abstract

It was a very dark year for EBM. One of the side effects of the Covid-19 pandemic is a severe compression of the evidences. Here are some worrying events. May 2020: the saga of hydroxychloroquine. October 2020: the nitazoxanide case. November 2020: Trump Administration Interferes on Expert Opinion. December 2020: the results of the trials on the first two vaccines were announced in press releases, leaving many scientific uncertainties. Peter Piot, head of the London School of Hygiene & Tropical Medicine noted that none of the CoViD-19 vaccines have offered much data to date. «It is frustrating that all of these announcements are delivered via press release, and not give us a chance to review the actual data. We desperately need total transparency on evidence and data», says Piot. Better now to relaunch the spread of EBM. In the issue, we have included the best EBM-based readings from the Club for Evidence-Based in Gastroenterology & Hepatology (ebgh.it).

MeSH terms

  • Access to Information*
  • Antiviral Agents / therapeutic use
  • Brazil
  • COVID-19 Drug Treatment*
  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Clinical Trials as Topic
  • Disclosure
  • Evidence-Based Medicine / trends*
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Italy
  • Nitro Compounds
  • Pandemics*
  • Politics
  • Propaganda
  • SARS-CoV-2*
  • Thiazoles / therapeutic use
  • United States

Substances

  • Antiviral Agents
  • COVID-19 Vaccines
  • Nitro Compounds
  • Thiazoles
  • Hydroxychloroquine
  • nitazoxanide